Enliven Therapeutics Q3 2021 Earnings Report
Key Takeaways
Imara Inc. reported a net loss of $13.6 million for the third quarter of 2021. The company completed patient enrollment in Phase 2b clinical trials for tovinontrine in sickle cell disease and beta-thalassemia and expects to report interim analysis data in the fourth quarter of 2021. They also introduced a new pipeline program, IMR-261, for sickle cell disease.
Completed patient enrollment in Ardent Phase 2b clinical trial of tovinontrine for sickle cell disease.
Completed patient enrollment in the transfusion dependent thalassemia (TDT) cohort of Forte Phase 2b clinical trial of tovinontrine for beta-thalassemia.
Closed $50 million public offering.
Introduced IMR-261, a novel oral clinic-ready Nrf2 activator, as a new pipeline asset.
Enliven Therapeutics
Enliven Therapeutics
Forward Guidance
Imara provided financial guidance for the full year 2021 and expects its cash, cash equivalents and investments as of September 30, 2021 will be sufficient to enable it to fund its planned operations into the first quarter of 2023.
Positive Outlook
- Full-year 2021 research and development expenses are expected to range between $40 million and $45 million.
- Full-year 2021 general and administrative expenses are expected to range between $12 million and $13 million.
- Cash, cash equivalents and investments as of September 30, 2021 are expected to be sufficient to fund planned operations into the first quarter of 2023.